Abstract
Objectives The aim of the study is to determine if there is an association between altered biomarkers and cardiovascular involvement in Latin American patients with MIS-C.
Design The researchers of this study conducted a retrospective cohort study.
Setting Secondary care maternal unit hospital in Monterrey, NL, Mexico.
Participants Any register of a Latin-American pediatric patient with MIS-C within the database from March 2019 to February 2022.
Primary and secondary outcome measures Cut, mean, odds ratio (OR), relative ratio (RR), 95% confidence interval (CI) and p values of inflammatory markers associated with cardiovascular affection in MIS-C. As a secondary outcome we measure being male as an independent risk factor.
Results None of the biomarkers and gender variables taken were significant (Table 1).
Conclusions The researchers’ analysis suggests there is no evidence of cause-effect association between admission biomarkers and the presence of cardiovascular affection in MIS-C. Remarkably, neutrophilia and ESR had a high odds ratio and a nearly significant p-value, which makes them ideal for further analysis with a bigger sample. Additionally, gender was included as a risk factor and was analyzed independently, nonetheless, it was not associated with a higher risk of presenting cardiovascular affection.
Strengths and limitations of this study
First study measuring the association of a series of available and economical biomarkers with a higher incidence of cardiovascular involvement in MIS-C in a Latin-American population.
Set ground for further research regarding the current treatment of MIS-C
Sample size non-representative.
Since this is an observational study we can’t fully control confounding and bias (e.j. reporting bias)
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Research Ethics Committee of the Hospital Regional Materno Infantil de Alta Especialidad with registration number DEISC-PR-19 01 21 065.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
* All authors have seen and approved the manuscript
karengonzalezmoc{at}gmail.com
o.tamez{at}gmail.com
villarreal.dra{at}gmail.com
Data Availability
The data presented in this study are available upon reasonable request from the corresponding author. The data is not publicly available due to privacy concerns.
